The diagnostics advisory committee reviewed the evidence available on the clinical and cost effectiveness of epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing to inform first ...
“イレッサ”、及び化学療法のいずれも以下の因子がILDの危険因子とされた。喫煙歴、既存の間質性肺炎、診断よりILD発症までの期間が6カ月以内、WHOのPS2以上、正常肺占有率が50％以下、年齢55歳以上、心血管系の合併症を有しているなどであった（表1）。
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: equality impact assessment - guidance Epidermal ...
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...
Mechelen, Belgium, 02 June 2025 - Biocartis NV ("Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Dizal Pharmaceuticals' lung cancer treatment "Zegfrovy" (ingredient name: Senbocertinib) has received accelerated approval from the U.S. Food and Drug Administration (FDA). After China in 2023, the ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する